About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: To find a complete list of Publications, please see listing here.

 

Found 7 results
Filters: Author is Saber, Wael  [Clear All Filters]
2022
T. - P. Lai, Verhulst, S., Dagnall, C. L., Hutchinson, A., Spellman, S. R., Howard, A., Katki, H. A., Levine, J. E., Saber, W., Aviv, A., and Gadalla, S. M., “Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202.”, Front Immunol, vol. 13, p. 966301, 2022.
R. Cusatis, Martens, M. J., Nakamura, R., Cutler, C. S., Saber, W., Lee, S. J., Logan, B. R., Shaw, B. E., Gregory, A., D'Souza, A., Hamilton, B. K., Horowitz, M. M., and Flynn, K. E., “Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.”, Am J Hematol, vol. 98, no. 2, pp. 229-250, 2022.
S. Putta, Young, B. A., Levine, J. E., Reshef, R., Nakamura, R., Strouse, C., Perales, M. - A., Howard, A., Pine, P., Shi, J., Zhang, P., Ho, V. T., and Saber, W., “Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.”, Transplant Cell Ther, vol. 29, no. 3, pp. 166.e1-166.e10, 2022.
2021
R. Reshef, Saber, W., Bolaños-Meade, J., Chen, G., Bin Chen, Y. -, Ho, V. T., Ponce, D. M., Nakamura, R., Martens, M. J., Hansen, J. A., and Levine, J. E., “Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.”, J Clin Oncol, vol. 39, no. 17, pp. 1878-1887, 2021.
R. Nakamura, Saber, W., Martens, M. J., Ramirez, A., Scott, B., Oran, B., Leifer, E., Tamari, R., Mishra, A., Maziarz, R. T., McGuirk, J., Westervelt, P., Vasu, S., Patnaik, M., Kamble, R., Forman, S. J., Sekeres, M. A., Appelbaum, F., Mendizabal, A., Logan, B., Horowitz, M., and Cutler, C., “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
2014
W. Saber, Le Rademacher, J., Sekeres, M., Logan, B., Lewis, M., Mendizabal, A., Leifer, E., Appelbaum, F. R., Horowitz, M. M., Nakamura, R., and Cutler, C. S., “Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.
E. Atallah, Bylow, K., Troy, J., and Saber, W., “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).”, Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.